Transient Ischemic Attack Reported with Paroxetine Use

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 617-620

  Manos, Gail H ^a   Wechsler, Steven M ^a  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

Paroxetine; SSRIs; TIA; Transient ischemic attack; Vasoconstriction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATENOLOL; DIGOXIN; HEPARIN; NITRIC OXIDE; PAROXETINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SIMVASTATIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CHRONIC PAIN; CLINICAL FEATURE; DISEASE PREDISPOSITION; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONIN RELEASE; TRANSIENT ISCHEMIC ATTACK; VASOCONSTRICTION; VASODILATATION;

ANTICOAGULANTS; DRUG INTERACTIONS; HEPARIN; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; WARFARIN;

EID: 1542429702     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D304     Document Type: Article

References (25)

1. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001;7:25-47.
2. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002;159:1702-10.
3. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-8.
4. Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3.
5. Molaie M. Serotonin syndrome presenting with migrainelike stroke. Headache 1997;37:519-21.
6. Conde Lopez VJM, Ballesteros Alcaide MC, Blanco Garrote JA, Marco Llorente J. [Cerebral infarction in an adolescent girl following an overdose of paroxetine and caffedrine combined with theoadrenaline.] Spanish. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998;26:333-8.
7. Reneman L, Habraken JBA, Majoie CBL, Booij J, den Heeten GJ. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol 2000;21:1001-7.
8. Schror K, Braun M. Platelets as a source of vasoactive mediators. Stroke 1990;21(suppl IV):32-5.
9. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 1995;35:541-72.
10. Tanner FC, Boulanger CM, Luscher TF. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost 1993;19:167-75.
11. Medgett IC, Fearn HJ, Rand MJ. Serotonin enhances sympathetic vasoconstrictor responses in rat isolated perfused tail artery by activation of postjunctional serotonin-2 receptors. Clin Exp Pharmacol Physiol 1984;11:343-6.
12. 1-type receptors in guinea pig basilar artery. J Cereb Blood Flow Metab 1989;9:713-6.
13. Jergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000;68:435-42.
14. Dalton SO, Johansen C, Mellenmkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;13:59-64.
15. Skop B, Brown T. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996;37:12-6.
16. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin-reuptake inhibitors and the risk of stroke: a population based case-control study. Stroke 2002;33:1465-73.
17. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
18. Lane R, Baldwin D. Selective serotonin-reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-21.
19. Hankey GJ. Management of the first-time transient ischaemic attack. Emerg Med 2001;13:70-81.
20. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin-reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
21. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70.
22. Drozdzik M, Domanski L, Wojcicki J, Pudlo A, Machoy P. Effect of unilateral nephrectomy on the pharmacokinetics of atenolol in humans. J Clin Pharmacol 2003;43:524-8.
23. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 2003;42:59-98.
24. Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicyclic acid. Clin Pharmacokinet 1989;17:327-44.
25. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.